318 related articles for article (PubMed ID: 17070267)
1. Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study.
Lazzeri M; Calò G; Spinelli M; Malaguti S; Guerrini R; Salvadori S; Beneforti P; Regoli D; Turini D
J Urol; 2006 Nov; 176(5):2098-102. PubMed ID: 17070267
[TBL] [Abstract][Full Text] [Related]
2. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study.
Lazzeri M; Calò G; Spinelli M; Guerrini R; Salvadori S; Beneforti P; Sandri S; Regoli D; Turini D
Urology; 2003 May; 61(5):946-50. PubMed ID: 12736013
[TBL] [Abstract][Full Text] [Related]
3. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study.
Lazzeri M; Calò G; Spinelli M; Guerrini R; Beneforti P; Sandri S; Zanollo A; Regoli D; Turini D
J Urol; 2001 Dec; 166(6):2237-40. PubMed ID: 11696742
[TBL] [Abstract][Full Text] [Related]
4. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
8. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.
Giannantoni A; Di Stasi SM; Stephen RL; Bini V; Costantini E; Porena M
J Urol; 2004 Jul; 172(1):240-3. PubMed ID: 15201783
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
[TBL] [Abstract][Full Text] [Related]
12. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial.
Silva C; Silva J; Ribeiro MJ; Avelino A; Cruz F
Eur Urol; 2005 Oct; 48(4):650-5. PubMed ID: 15961217
[TBL] [Abstract][Full Text] [Related]
13. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
14. Intravesical vanilloids and neurogenic incontinence: ten years experience.
Lazzeri M; Spinelli M; Zanollo A; Turini D
Urol Int; 2004; 72(2):145-9. PubMed ID: 14963356
[TBL] [Abstract][Full Text] [Related]
15. Gabapentin treatment of neurogenic overactive bladder.
Carbone A; Palleschi G; Conte A; Bova G; Iacovelli E; Bettolo CM; Pastore A; Inghilleri M
Clin Neuropharmacol; 2006; 29(4):206-14. PubMed ID: 16855422
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2).
Kennelly M; Cruz F; Herschorn S; Abrams P; Onem K; Solomonov VK; Del Rosario Figueroa Coz E; Manu-Marin A; Giannantoni A; Thompson C; Vilain C; Volteau M; Denys P;
Eur Urol; 2022 Aug; 82(2):223-232. PubMed ID: 35400537
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity.
Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Marque P; Rischmann P; Gamé X
World J Urol; 2016 May; 34(5):755-61. PubMed ID: 26282099
[TBL] [Abstract][Full Text] [Related]
18. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
[TBL] [Abstract][Full Text] [Related]
19. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study.
de Sèze M; Gallien P; Denys P; Labat JJ; Serment G; Grise P; Salle JY; Blazejewski S; Hazane C; Moore N; Joseph PA
Neurourol Urodyn; 2006; 25(7):752-7. PubMed ID: 16986136
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
